Targeted Therapy in Non-small Cell Lung Cancer
Series: Oxford American Pocket Notes;
- Publisher's listprice GBP 11.49
-
5 489 Ft (5 227 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 549 Ft off)
- Discounted price 4 940 Ft (4 704 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
5 489 Ft
Availability
Uncertain availability. Please turn to our customer service.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher OUP USA
- Date of Publication 13 October 2011
- ISBN 9780199743087
- Binding Paperback
- No. of pages88 pages
- Size 165x104x8 mm
- Weight 68 g
- Language English 0
Categories
Short description:
Part of the Oxford American Pocket Notes series, this ultra-concise guide contains insightful, easily accessible, evidence-based discussion on the mechanisms and proper use for the newest agents to treat non-small cell lung cancer.
MoreLong description:
Although lung cancer remains the leading cancer killer in the United States, recent years have seen a number of developments that may portend future clinical benefit. These include renewed interest in CT-based screening approaches, the use of stereotactic radiation for early stage tumors, proposed revisions to the lung cancer staging system, and the development of molecular methods to predict chemotherapy sensitivity. Perhaps the most significant advance in the
treatment of this challenging disease is the introduction of molecularly targeted therapies, a term that includes monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). Specifically, drugs targeting the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF)
are now FDA-approved for the treatment of advanced non-small cell lung cancer (NSCLC). Although these agents are generally better tolerated than conventional chemotherapy, their use requires a clear understanding of clinical data, mechanism, patient selection, drug interactions, and toxicities.
Part of the Oxford American Pocket Notes series, this volume provides a clinically-oriented overview of NSCLC targeted therapies to practicing oncologists. This ultra-concise guide contains insightful, easily accessible, evidence-based discussion on the mechanisms and proper use for the newest agents to treat NSCLC. Key features include bulleted lists as well as numerous tables and figures to illustrate key points and provide the clinician with essential patient care
tools.
this is a very useful pocket guide for those attempting to get this rapidly evolving field into focus and to understand the pivotal papers that underpin the more recent advances.
Table of Contents:
Introduction
Targeted Therapies
Molecular Targets in Oncology
Molecular Targets in NSCLC
Clinical Experience with Targeted Therapies in NSCLC
Patient Selection for Targeted Therapies in NSCLC
Administration and Toxicities of Targeted Therapies for NSCLC
Internet Resources
Access to Complete Prescribing Information
Appendix
References
